Full Press Release Details
Melbourne, Australia,
November 13, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is
pleased to invite shareholders to attend an investor webinar on The Watchlist, to be held on Tuesday 14th November 2023, 1:00pm AEDT/
CEO, Steven Lydeamore
will provide an overview and update on the business and upcoming milestones.
Following the presentation,
attendees will have the opportunity to ask questions directly to Mr Lydeamore during a moderated Q & A session.
be viewed live via zoom & you register via the link below.
of the webinar will be made available following the event.
release by the Board of Immuron Limited.
Chief Executive Officer
Ph: +61 (0)3 9824 5254
is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveller's diarrhoea,
a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.
Travelan is a highly purified tabletised preparation of hyperimmune bovine antibodies and other factors, which when taken
with meals bind to diarrhoea-causing bacteria and prevent colonisation and the pathology associated with traveller's diarrhoea.
In Australia, Travelan is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated
to reduce the risk of Traveller's Diarrhoea, reduce the risk of minor gastrointestinal disorders and is antimicrobial. In Canada,
Travelan is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Traveller's
Diarrhoea. In the U.S., Travelan is sold as a dietary supplement for digestive tract protection.
Traveller's Diarrhoea
Diarrhoea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping,
bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing
a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections
with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are
often confused with Traveller's Diarrhoea as they may be contracted while travelling and initial symptoms are often indistinguishable.
Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered
targeted polyclonal antibodies for the treatment of infectious diseases.
more information visit: http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to
our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements
are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic
agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting
and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers;
our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional
funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is
based, except as required by law.